Nagase Satoru, Ohta Tsuyoshi, Takahashi Fumiaki, Enomoto Takayuki
Department of Obstetrics and Gynecology, Yamagata University, Faculty of Medicine, Yamagata, Japan.
Clinical Research, Innovation and Education Center, Tohoku University Hospital, Miyagi, Japan.
J Obstet Gynaecol Res. 2019 Feb;45(2):289-298. doi: 10.1111/jog.13863. Epub 2018 Nov 13.
To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2015 and the Annual Treatment Report for 2010 on the outcomes of patients who started treatment in 2010.
The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment was initiated in 2015 were analyzed retrospectively. Survival of the patients who started treatment in 2010 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxson tests.
Treatment was initiated in 2015 for 7527 patients with cervical cancer, 10 119 with endometrial cancer, 6424 with ovarian cancer and 2181 with ovarian borderline tumors. This clinicopathological information was summarized as the Patient Annual Report. Prognoses were analyzed across 4309 patients with cervical cancer, 5054 with endometrial cancer and 3423 with ovarian cancer, whose treatment was initiated in 2010. The 5-year survival rates of the patients with cervical cancer were 92.1%, 74.2%, 52.0%, and 29.8% for stages I, II, III, and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 94.3%, 88.8%, 74.0% and 26.6% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 88.5%, 80.1%, 46.3% and 36.2% for stages I, II, III and IV, respectively.
The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.
为提供包括日本妇科恶性肿瘤趋势在内的信息，我们在此呈现2015年年度患者报告以及2010年年度治疗报告，内容涉及2010年开始治疗的患者的治疗结果。
日本妇产科学会维持一个年度肿瘤登记处，收集来自各个参与机构的妇科恶性肿瘤信息。对2015年开始治疗的患者数据进行回顾性分析。采用Kaplan-Meier、对数秩检验和Wilcoxson检验分析2010年开始治疗的患者的生存率。
2015年开始治疗的宫颈癌患者有7527例，子宫内膜癌患者有10119例，卵巢癌患者有6424例，卵巢交界性肿瘤患者有2181例。这些临床病理信息被汇总为患者年度报告。对2010年开始治疗的4309例宫颈癌患者、5054例子宫内膜癌患者和3423例卵巢癌患者的预后进行了分析。宫颈癌患者I、II、III和IV期的5年生存率分别为92.1%、74.2%、52.0%和29.8%。子宫内膜癌患者I、II、III和IV期的5年生存率分别为94.3%、88.8%、74.0%和26.6%。卵巢癌（表面上皮-间质肿瘤）患者I、II、III和IV期的5年生存率分别为88.5%、80.1%、46.3%和36.2%。
年度肿瘤报告是一项重要的调查，提供了日本妇科恶性肿瘤趋势的相关知识。
